.jpg "ConforMIS (NASDAQ: CFMS)")
Oppenheimer analyst Steven Lichtman maintained a Buy rating on ConforMIS (NASDAQ: CFMS) today. The company’s shares closed yesterday at $1.28, close to its 52-week low of $0.88.
According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 53.8% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Currently, the analyst consensus on ConforMIS is a Strong Buy with an average price target of $3.33.
See today’s analyst top recommended stocks >>
Based on ConforMIS’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.06 million. In comparison, last year the company had a GAAP net loss of $12.09 million.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ConforMIS, Inc. is a holding company, which engages in the development, manufacture, and sale of joint replacement implants. Its products include iTotal, iUni and iDuo, and iJig Instrumentation. The company was founded Philipp Lang in 2004 and is headquartered in Bedford, MA.
